188
Views
7
CrossRef citations to date
0
Altmetric
Gastrointestinal cancer

NQO1 rs1800566 C>T polymorphism was associated with a decreased risk of esophageal cancer in a Chinese population

, , , , , , , , , , & show all
Pages 317-322 | Received 28 Sep 2013, Accepted 05 Dec 2013, Published online: 19 Dec 2013

References

  • Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou X, et al. Esophageal cancer incidence and mortality in china, 2009. J Thorac Dis 2013;5:19–26.
  • Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004;1:e65.
  • Joseph P, Jaiswal AK. NAD(P)H:Quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci USA 1994;91:8413–17.
  • Asher G, Lotem J, Cohen B, Sachs L, Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by nadh quinone oxidoreductase 1. Proc Natl Acad Sci USA 2001;98:1188–93.
  • Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 2000;29:246–53.
  • Cresteil T, Jaiswal AK. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 1991;42:1021–7.
  • Danson S, Ward TH, Butler J, Ranson M. DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev 2004;30:437–49.
  • Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 1999;9:113–21.
  • Sameer AS, Shah ZA, Syeed N, Rasool R, Afroze D, Siddiqi MA. NAD(P)H:Quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and colorectal cancer predisposition in the ethnic kashmiri population. Asian Pac J Cancer Prev 2010;11:209–13.
  • Yanling H, Yuhong Z, Wenwu H, Lei X, Mingwu C. NQO1 C609T polymorphism and esophageal cancer risk: a huge review and meta-analysis. BMC Med Genet 2013;14:31.
  • Iida A, Sekine A, Saito S, Kitamura Y, Kitamoto T, Osawa S, et al. Catalog of 320 single nucleotide polymorphisms (SNPs) in 20 quinone oxidoreductase and sulfotransferase genes. J Hum Genet 2001;46:225–40.
  • Harada S, Fujii C, Hayashi A, Ohkoshi N. An association between idiopathic parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione s-transferase m1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun 2001;288:887–92.
  • Yuan W, Xu L, Chen W, Wang L, Fu Z, Pang D, et al. Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat 2011;125:467–72.
  • Lajin B, Alachkar A. The NQO1 polymorphism C609t (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis. Br J Cancer 2013;109:1325–37.
  • de Aguiar Goncalves BA, Vasconcelos GM, Thuler LC, Andrade C, Faro A, Pombo-de-Oliveira MS, et al. NQO1 rs1800566 (C609T), PON1 rs662 (Q192R), and PON1 rs854560 (l55M) polymorphisms segregate the risk of childhood acute leukemias according to age range distribution. Cancer Causes Control 2012;23:1811–19.
  • Gaikwad NW, Rogan EG, Cavalieri EL. Evidence from esi-ms for nqo1-catalyzed reduction of estrogen ortho-quinones. Free Radic Biol Med 2007;43:1289–98.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.